Search

Introduction: De Quervain’s tenosynovitis is a disorder of the tendons of the first dorsal compartment of the wrist that causes pain and functional disability, which may be refractory to conservative treatments. Platelet-rich plasma (PRP) has become increasingly popular in sports Medicine and Orthopaedic practice as treatment for muscle, tendon, and ligament injuries, and has received media attention because of its promise as a regenerative therapy. Objective: To determine the efficacy of intralesional injection of platelet rich plasma (PRP) in patients of De Quervain’s tenosynovitis Material & Methods: Th is descriptive series were conducted at Department of Orthopedics and Spine centre, Ghurki Trust Teaching Hospital, Lahore Pakistan from January 2018 to July 2019. Total 100 patients fulfilling the inclusion criteria were included in the study. Platelet rich plasma was obtained after centrifuging the blood taken from the patient. Under aseptic measures a phlebotomist obtained blood in vacutainer. Vacutainer was centrifuged and middle zone containing platelet rich plasma was aspirated in a 5 ml disposable syringe. Th e patient received intralesional injection plus oral non-steroidal anti-inflammatory drug. Th e included patients were evaluated three weeks after treatment initiation for pain relief. Time of start of symptoms for more than one year and history of diabetes was treated as effect modifier along with age and gender. Results: Mean age of patients was 41.26±11.26 years. Th ere were 53(53%) patients in the study who were diabetic. Efficacy of treatment was seen in 85(85%) patients. However in 15(15%) patients Intralesional injection of platelet rich plasma was not effective. Efficacy of treatment was not significantly associated with age, gender, diabetes status and duration of symptoms. Conclusion: Keeping in mind the results of this study and as well as the results of pilot study conducted prior to this study intralesional injection of platelet rich plasma can be effectively used for de Quervain’s tenosynovitis. However further studies are needed to put this treatment modality in the first line treatment options for patients with de Quervain’s tenosynovitis [ABSTRACT FROM AUTHOR]